136 related articles for article (PubMed ID: 33971041)
1. Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
Hall KH; Brooks A; Waller EK
Am J Hematol; 2021 Aug; 96(8):E293-E295. PubMed ID: 33971041
[No Abstract] [Full Text] [Related]
2. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
[TBL] [Abstract][Full Text] [Related]
3. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia.
Kantarjian HM; Jabbour EJ; Lipton JH; Castagnetti F; Brümmendorf TH
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):285-297. PubMed ID: 38278737
[TBL] [Abstract][Full Text] [Related]
4. High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation.
Uchida Y; Koyama D; Manabe K; Suzuki K; Asano N; Endo M; Fukatsu M; Sano T; Hayashi K; Takano M; Takahashi H; Kimura S; Ikezoe T
Intern Med; 2024 Mar; 63(5):717-720. PubMed ID: 37407456
[TBL] [Abstract][Full Text] [Related]
5. Isolated knuckle hyperpigmentation associated with bosutinib.
Sharma V; Mahajan S; Bagrodia V
BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38417948
[No Abstract] [Full Text] [Related]
6. The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia.
Fernando F; Innes AJ; Claudiani S; Pryce A; Hayden C; Byrne J; Gallipoli P; Copland M; Apperley JF; Milojkovic D
Bone Marrow Transplant; 2023 Jul; 58(7):826-828. PubMed ID: 37015970
[No Abstract] [Full Text] [Related]
7. JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients.
Gallipoli P
Leuk Res; 2018 Dec; 75():71-72. PubMed ID: 30392903
[No Abstract] [Full Text] [Related]
8. Chronic myeloid leukemia: room for improvement?
Baccarani M; Pane F; Rosti G; Russo D; Saglio G
Haematologica; 2017 Jul; 102(7):1131-1133. PubMed ID: 28655808
[No Abstract] [Full Text] [Related]
9. In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.
Han HJ; Kim JJ; Pyne D; Travas A; Ambalavanan A; Kimura S; Deininger MW; Kim JW; Kim DDH
Leukemia; 2024 Feb; 38(2):412-415. PubMed ID: 38155246
[No Abstract] [Full Text] [Related]
10. Response to Pfirrmann et al.'s comment on How should we interpret conclusions of TKI-stopping studies.
Chen J; Gale RP
Leukemia; 2024 Feb; 38(2):463-464. PubMed ID: 38151660
[No Abstract] [Full Text] [Related]
11. Asciminib for the treatment of patients with chronic myeloid leukemia.
Cortes J
Clin Adv Hematol Oncol; 2021 Apr; 19(4):207-208. PubMed ID: 33989269
[No Abstract] [Full Text] [Related]
12. Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.
Hughes TP; Clementino NCD; Fominykh M; Lipton JH; Turkina AG; Moiraghi EB; Nicolini FE; Takahashi N; Sacha T; Kim DW; Fellague-Chebra R; Tiwari R; Bouard C; Mahon FX
Leukemia; 2021 Jun; 35(6):1631-1642. PubMed ID: 33980976
[TBL] [Abstract][Full Text] [Related]
13. Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.
Etienne G; Faberes C; Bauduer F; Adiko D; Lifermann F; Dagada C; Lenoir C; Schmitt A; Klein E; Fort MP; Bijou F; Turcq B; Robbesyn F; Durrieu F; Versmée L; Madene S; Moldovan M; Katsahian S; Charles-Nelson A; Lascaux A; Mahon FX; Dulucq S
Cancer Med; 2021 Jun; 10(11):3635-3645. PubMed ID: 33988316
[TBL] [Abstract][Full Text] [Related]
14. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia.
Jain N; Maiti A; Ravandi F; Konopleva M; Daver N; Kadia T; Pemmaraju N; Short N; Kebriaei P; Ning J; Cortes J; Jabbour E; Kantarjian H
Am J Hematol; 2021 Aug; 96(8):1000-1007. PubMed ID: 33991360
[TBL] [Abstract][Full Text] [Related]
15. Sirtuin1 and Chronic Myeloid Leukemia: a Comprehensive Glance at Drug Resistance.
Abbasian S; Shokrgozar N; Tamaddon G
Clin Lab; 2021 May; 67(5):. PubMed ID: 33978360
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a Candidate Containing an (
Zhang D; Li P; Gao Y; Song Y; Zhu Y; Su H; Yang B; Li L; Li G; Gong N; Lu Y; Shao H; Yu C; Huang H
J Med Chem; 2021 Jun; 64(11):7434-7452. PubMed ID: 34011155
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review.
Hsu CC; Hsu JF; Wu KL
Respirol Case Rep; 2021 Jun; 9(6):e00753. PubMed ID: 33976882
[TBL] [Abstract][Full Text] [Related]
18. Suspected chronic myeloid leukemia-like BCR-ABL1-positive acute lymphoblastic leukemia.
Keino D; Kinoshita A; Sudo A; Ohyama R; Mori T
Pediatr Int; 2021 Jun; 63(6):728-729. PubMed ID: 34038034
[No Abstract] [Full Text] [Related]
19. A clinical appraisal of chronic myeloid leukaemia (CML)-related death and CML-specific death-Are they synonymous?
Eşkazan AE
Int J Clin Pract; 2021 Jun; 75(6):e14217. PubMed ID: 33998756
[No Abstract] [Full Text] [Related]
20. Anti-chronic myeloid leukemia activity and quantitative structure-activity relationship of novel thiazole aminobenzamide derivatives.
Zhang Y; Liu J; Wu X; Yang S; Li Y; Liu S; Zhu S; Cao X; Xie Z; Lei X; Huang H; Peng J
Bioorg Med Chem Lett; 2021 Jul; 44():128116. PubMed ID: 34015503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
